Title |
Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
|
---|---|
Published in |
Hepatic medicine evidence and research, May 2018
|
DOI | 10.2147/hmer.s130103 |
Pubmed ID | |
Authors |
Nimisha Sulejmani, Syed-Mohammed Jafri |
Abstract |
Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection. Efficacy of grazoprevir/elbasvir has been proven in patients with cirrhosis, patients who have previously failed treatment with peginterferon and ribavirin (RBV), patients with end-stage renal disease and patients with HIV co-infection. Data have shown a high barrier to resistance despite the presence of resistance-associated substitutions. Grazoprevir/elbasvir represents a very promising regimen for treatment of HCV infection. This review provides a summary of pharmacology, efficacy, and safety of grazoprevir/elbasvir for the treatment of HCV infection. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 21 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 14% |
Student > Bachelor | 3 | 14% |
Student > Master | 2 | 10% |
Student > Ph. D. Student | 1 | 5% |
Researcher | 1 | 5% |
Other | 1 | 5% |
Unknown | 10 | 48% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 24% |
Biochemistry, Genetics and Molecular Biology | 3 | 14% |
Psychology | 1 | 5% |
Nursing and Health Professions | 1 | 5% |
Unknown | 11 | 52% |